PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

December 19, 2019

Primary Completion Date

January 23, 2024

Study Completion Date

January 23, 2024

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

BNT112

Intravenous bolus injection

DRUG

Cemiplimab

Intravenous infusion

Trial Locations (22)

1062

Magyar Honvédség Egészségügyi Központ (MH EK Honvédkórház), Budapest

1083

Semmelweis Egyetem, Belgyógyászati Klinika, Budapest

2800

Szent Borbála Kórház, Tatabánya

4032

Onkológiai Klinika, Debrecen

4400

Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház, Nyíregyháza

15215

University of Pittsburgh Cancer Inst., Pittsburgh

22908

University of Virginia Cancer Center, Charlottesville

33136

University of Miami Hospital & Clinics /Sylvester Comprehensive Cancer Center, Miami

48149

Universitätsklinikum Münster, Münster

53105

Universitätsklinikum Bonn, Bonn

60590

Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt

72076

Universitätsklinikum Tübingen, Tübingen

72622

Studienpraxis Urologie, Nürtingen

78229

Urology San Antonio P.A., San Antonio

82152

Urologische Klinik Planegg, Planegg

85724

The University of Arizona Cancer Center, Tucson

CB2 0RE

Cancer Research UK Cambridge Centre, Cambridge

CF14 2TL

Velindre Cancer Centre (VCC), Cardiff

G12 0YN

University of Glasgow, Beatson WoS Cancer Centre, Glasgow

NW1 2PG

University College London Hospitals, London

SW3 6JJ

The Royal Marsden Hospital, London

SO16 6YD

University Hospital Southampton - Southampton General Hospital, Southampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BioNTech SE

INDUSTRY